Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

ClinicalTrials.gov ID: NCT04010305

Public ClinicalTrials.gov record NCT04010305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine Efficacy, Pharmacokinetics and Safety of BXCL501 in Agitation Associated With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a two-stage adaptive Phase Ib trial design, that will identify two doses (lowest dose with clinical benefit and highest safe dose) in a first stage and better evaluate safety, tolerability and variability of effect in the second stage.

Study identification

NCT ID
NCT04010305
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
BioXcel Therapeutics Inc
Industry
Enrollment
135 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 21, 2019
Primary completion
Jul 30, 2019
Completion
Jul 30, 2019
Last update posted
Aug 10, 2026

2019

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
BioXcel Clinical Research Site Little Rock Arkansas 72211
BioXcel Clinical Research Site Cerritos California 90703
BioXcel Clinical Research Site Lemon Grove California 91945
BioXcel Clinical Research Site Long Beach California 90806
BioXcel Clinical Research Site Orange California 92868
BioXcel Clinical Research Site Miami Lakes Florida 33016
BioXcel Clinical Research Site Atlanta Georgia 30331
BioXcel Clinical Research Site Gaithersburg Maryland 20877
BioXcel Clinical Research Site Flowood Mississippi 39232
BioXcel Clinical Research Site Berlin New Jersey 08009
BioXcel Clinical Research Site Austin Texas 78754
BioXcel Clinical Research Site Richardson Texas 75080

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04010305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04010305 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →